Dopamine "renal-dose": An appraisal of current concepts, controversies & concerns

Dialysis and Transplantation

Volumn 31, Issue 9, 2002, Pages

  Saxena, Anil Kumar ^a  

^a KING FAHAD HOSPITAL   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CONTRAST MEDIUM; DOPAMINE; DOPAMINE RECEPTOR; PLACEBO; RECOMBINANT INTERLEUKIN 2;

ACUTE KIDNEY FAILURE; ANGIOCARDIOGRAPHY; CANCER; CANCER PATIENT; CLINICAL TRIAL; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CRITICAL ILLNESS; DIABETES MELLITUS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG INFUSION; DRUG MECHANISM; ENDOCRINE DISEASE; GLOMERULUS FILTRATION RATE; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HIGH RISK PATIENT; HUMAN; INTENSIVE CARE UNIT; INTESTINE ISCHEMIA; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; META ANALYSIS; MULTICENTER STUDY; NEPHROTOXICITY; OLIGURIA; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SEPTIC SHOCK; VASODILATATION;

EID: 0036709214     PISSN: 00902934     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. Trim CM, Moore JN, Clark ES. Renal effects of dopamine infusion in conscious horses. Equine Vet J 1989; 7:124-128.
2. McNay JL, Mc Donald RH, Goldberg LI. Direct renal vasodilatation produced by dopamine in dog. Circ Res 1965; 16:510-517.
3. McDonald RH, Goldberg LI, McNay JL, Tuttle EP. Effects of dopamine in man: Augmentation of sodium excretion, glomerular filtration rate and renal plasma flow. J Clin Invest 1964; 43:1116-1124.
4. Hegde SS, Lokhandwala MF. Renal dopamine and sodium excretion. Am J Hypertens 1990; 3:78-81.
5. Denton MD, Chertow GM, Brady HR. Renal-dose dopamine for the treatment of ARF: Scientific rationale, experimental studies and clinical trials. Kidney Int 1996; 50:4-14.
6. Goldberg LI. Cardiovascular and renal actions of dopamine: Potential clinical applications. Pharmacol Rev 1972; 24:1-29.
7. Eble JN. A proposed mechanism for depressor effect of dopamine in anaesthetized dog. J Pharmacol Exp Ther 1964; 145:64-70.
8. Brodde OE. Affinities of dopamine agonists and antagonists for peripheral dopamine receptors. In: Cardiovascular Function of Peripheral Dopamine Receptors, Hieble JP, (ed.). New York: Marcel Dekker, 1989, pp 27-72.
9. Olsen NV. Effect of dopamine on renal hemodynamics, tubular function and sodium excretion in normal humans. Dan Med Bull 1998; 45:282-297.
10. 1 dopamine receptor-mediated natriuresis. Clin Exp Hypertens 1998; 20:259-271.
11. Jose PA, Raymond JR, Bates MD, Aperia A, Felder RA, Carey RM. The renal dopamine receptors. JAm Soc Nephrol 1992; 2:1265-1278.
12. + ATPase activity in proximal tubules from rat's kidney. Acta Physiol Scand 1988; 132:441-443.
13. Laradi A, Sakhrani LM, Massry SG. Effect of dopamine on sodium uptake by renal proximal tubule cells of rabbit. Miner Electrolyte Metab 1986; 12:303-307.
14. Murphy B. Dopamine: A role in pathogenesis and treatment of hypertension. J Hum Hypertens 2000; 14:47-50.
15. Edwards RM. Comparison of effect of Fenoldopalm, SKF R-87516 and dopamine on renal arterioles in vitro. Eur J Pharmacol 1986; 126:167-170.
16. Vargo DL, Brater DC, Rudy DW, Swan SK. Dopamine does not enhance furosemide-induced natriuresis in patients with congestive heart failure. J Am Soc Nephrol 1996; 7:1032-1037.
17. Ratcliffe PJ. Pathophysiology of acute renal failure. In: Oxford Textbook of Clinical Nephrology, Cameron JS, Davidson AM, Grunfeld JP, Kerr D, Ritz E (eds.). Oxford: Oxford University Press, 1998, pp 1531-1556.
18. Oken DE. Hemodynamic basis of human acute renal failure (vasomotor nephropathy). Am J Med 1984; 74:702-710.
19. Venkatakrishnan U, Chen C, Lokhandwala MF. The role of intrarenal nitric oxide in the natriuretic response to dopamine receptor activation. Clin Exp Hypertens 2000; 3:309-324.
20. D'Orio V, el Allaf D, Juchmes J, Marcelle R. The use of low-dose dopamine in intensive care medicine. Arch Int Physiol Biochim 1984; 92:11-20.
21. De La Cal MA, Miravelles E, Pascual T, Esteban A, Ruiz-Santana S. Dose-related hemodynamic and renal effects of dopamine in septic shock. Crit Care Med 1984; 12:22-25.
22. De Werra P, Bracco D. Renal-protective dose of dopamine: Myth or reality? Rev Med Suisse Romande 1999; 119:203-208.
23. Stein JH, Gottschall J, Osgood RW, Ferris TF. Pathophysiology of nephrotoxic model of acute renal failure. Kidney Int 1975; 8:27-41.
24. Polsson J, Ricksten SE, Houltz E, Lundin S. Effects of dopamine, dopexamine and dobutamine on renal excretory function during experimental sepsis in conscious rats. Acta Anaesthesiol Scand 1997; 47:392-398.
25. Linder A, Cutler RE, Goodman WG: Synergism of dopamine plus furosemide in preventing acute renal failure in the dog. Kidney Int 1979; 16:158-166.
26. Drieman JC, Van Kan FJPM, Thijssen HHW. Regional hemodynamic effects of dopamine and its pro-drug L-Dopa and GluDopa in the rat and in glycerol-treated rat as model for acute renal failure. Br J Pharmacol 1994; 111:1117-1122.
27. Neiberger RE, Passmore JC. Effect of dopamine on canine intra-renal blood flow distribution during hemorrhage. Kidney Int 1979; 15:219-226.
28. Horwitz D, Fox SM, Goldberg LI. Effects of dopamine in man. Cir Res 1962; 10:237-243.
29. Tally RC, Forland M, Beller B. Reversal of acute renal failure with combination of intravenous dopamine and diuretics. Clin Res 1970; 18:518.
30. Parker S, Carlon GC, Isaacs M, Howland WS, Kahn RC. Dopamine administration in oliguria and oliguric renal failure. Crit Care Med 1981; 9:630-632.
31. Dasta J, Kirby M. Pharmacology and therapeutic use of low-dose dopamine. Pharmacotherapy 1986; 6:304.
32. Davis RF, Lappas DG, Kirklin JK, Buckley MJ, Lowenstein E. Acute oliguria after cardiopulmonary bypass: Renal functional improvement with low-dose dopamine infusion. Crit Care Med 1994; 22:61-66.
33. Henderson IS, Beattie TJ, Kennedy AC. Dopamine hydrochloride in oliguric states. Lancet 1980; 2:827-828.
34. Linder A. Synergism of dopamine and furosemide in oliguric acute renal failure. Nephron 1983; 33:121-126.
35. Graziani G, Cantaluppi A, Casate S, Dopamine and furosemide in oliguric acute renal failure. Nephron 1984; 37:39-42.
36. Flankbaum L, Choban PS, Dasta JF. Quantitative effects of low-dose dopamine on urine output in oliguric surgical intensive care unit patients. Crit Care Med 1994; 22:61-66.
37. Palmieri S, Morabito A, Lauria R. Low-dopamine induces early recovery of recombinant interleukin-2 impaired renal function. Eur J Cancer 1993; 29:1119-1122.
38. Chertow GM, Sayegh MH, Allgren RL, Lazarus JM. Is the administration of dopamine associated with adverse or favorable outcomes in acute renal failure? Auriculin Anaritide Acute Renal Failure Study Group. Am J Med 1997; 102:320-322.
39. Marik PE, Iglesias J. Low-dose dopamine does not prevent acute renal failure in patients with septic shock and oliguria. NORASEPT II Study Investigators. Am J Med 1999; 107:387-390.
40. Kellum JA, Dekker MJ. Use of dopamine in acute renal failure: A meta-analysis. Crit Care Med 2001; 29:1526-1531.
41. Bellomo R, Chapman M, Finger S, Hickling K, Myburgh J. Low-dose dopamine in patients with early renal dysfunction: A placebo controlled randomized trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical trial group. Lancet 2000; 356:2112-2113.
42. Lin SM, Lee CS, Kao PF. Low-dose dopamine infusion in cirrhosis with refractory ascitis. Int J Clin Pract 1998; 52:533-536.
43. Parks RW, Diamond T, McCrony DC, Johnston GW, Rowland BJ. Prospective study of post-operative renal function in obstructive jaundice and the effect of perioperative dopamine. Br J Surg 1994; 81:437-439.
44. Lassnigg A, Donner E, Grubhofer G, Presterl E, Hiesmayr M. Lack of renoprotective effect of dopamine during cardiac surgery. J Am Soc Nephrol 2000; 11:97-104.
45. Stevens MA, McCullough PA, Tobin KJ, Speck JP, West veer DC, Guido-Allen DA. A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: Results of P.R.I.N.C.E. (Prevention of Radiocontrast-Induced Nephropathy Evaluation Study) Clinical Trial. J Am Coll Cardiol 1999; 33:403-411.
46. Gare M, Haviv YS, Ben-Yehuda, Rubinger D, Bdolah-Abrham T, Fuchs SO. Renal effects of low-dose dopamine in high-risk patients undergoing coronary angiography. J Am Coll Cardiol 1999; 34:1682-1688.
47. Cormier JN, Hurst R, Vasselli J, Lee D, Kim CJ, McKee M. A prospective randomized evaluation of prophylactic use of low-dose dopamine in cancer patients receiving interleukin-2. J Immunother 1997; 20:292-300.
48. Somlo G, Doroshow JH, Lev-Ran A, Ahn DC, Hwang I, Raschko JW. Effect of low-dose dopamine on high-dose cisplatin-induced electrolyte wasting, ototoxicity and epidermal growth factor excretion: A randomized, placebo-controlled, double-blind trial. J Clin Oncol 1995; 13:1231-1237.
49. Tang AT, El-Gamal A, Keevil B, Yonan N, Deiraniya AK. The effect of 'renal-dose' dopamine on renal tubular function following cardiac surgery: Assessed by measuring retinal binding protein (RBP). Eur J Cardiothoracic Surg 1999; 15:717-21.
50. Baldwin L, Henderson A, Hickman P. Effect of postoperative dopamine on renal function after elective major vascular surgery. Ann Intern Med 1994; 120:744-747.
51. Kedieva VS, Friedman L, Margolius LP, Jackson SA, Morrel DF. The effects of dopamine on graft function in patients undergoing renal transplantation. Anesth Analog 1993; 76:362-367.
52. Polson RJ, Park GR, Lindop MJ, Farman JV, Calne RY, Williams R. The prevention of renal impairment in patients undergoing orthotopic liver grafting by infusion of low-dose dopamine. Anaesthesia 1987; 42:15-19.
53. Swygert TH, Roberts LC, Valek TR. Effect of intraoperative low-dose dopamine on renal function in liver transplant recipients. Anaesthesiology 1991; 75:571-576.
54. Devins SS, Miller A, Herndon BL, O'Toole L, Reisz G. Effect of dopamine on T-Lymphocyte proliferative responses and serum prolactin concentrations in critically ill patients. Crit Care Med 1992; 20:1664-1669.
55. Van Den Berghe G, de Zegher F. Anterior pituitary functions during critical illness and dopamine treatment. Crit Care Med 1996; 24:1580-1590.
56. Gelfman DM, Ornato JP, Gonzales ER. Dopamine-induced atrioventricular conduction in atrial fibrillation-flutter. Clin Cardiol 1987; 10:672-73.
57. Olson LG, Hensley MJ, Saunders NA. Ventilatory responsiveness to hypercapnic hypoxia during dopamine infusion in humans. Am Rev Respir Dis 1982; 126:783-787.
58. Thompson BT, Cockrill BA. Renal-dose dopamine a siren song? Lancet 1994; 344:7-8.
59. Segal JM, Phang PT, Walley KR. Low-dose dopamine hastens onset of gut ischemia in porcine model of hemorrhagic shock. J Appl Physiol 1992; 73:1159-1164.
60. Fiddian-Green RG. Studies in splanchnic ischemia and multiple organ failure. In: Splanchnic Ischemia and Multiple Organ Failure, Marston A, Bulkley GB, Fiddian-Green RG, et al. (eds.). London: Edward Arnold, 1989, pp 349-363.
61. Winkler MJ, Trunkey DD. Dopamine gangrene, association with disseminated intravascular coagulation. Am J Surg 1981; 142:588-591.
62. Stetson JB, Reading GP. Avoidance of vascular complications associated with the use of dopamine. Can Anaesth Soc J 1977; 24:727-733.
63. Cuthburtson BH, Noble DW. Dopamine in oliguria. Brit oliguria. Brit Med J 1997; 314:690-691.
64. Juste R, Moran L, Hooper J, Soni N. Dopamine clearance in critically ill infants and children. Intensive Care Med 1997; 23:80.
65. Orme ML, Breckenridge A, Dollery CT. The effect of long-term administration of dopamine on renal function in hypertensive patients. Eur J Clin Pharmacol 1973; 6:150-155.